{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:00:31Z","timestamp":1790269231497,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Cardiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Sacubitril\/valsartan is increasingly used in pediatric cardiac patients, though its acute physiologic effects in critically ill children remain incompletely characterized. We sought to define the early hemodynamic and tissue-level response to sacubitril\/valsartan using high-fidelity physiologic data. This was a retrospective study of children in a cardiac intensive care unit with continuous physiologic monitoring. High-resolution data were temporally aligned to the time of sacubitril\/valsartan initiation. Locally weighted regression was used to characterize percent change in physiologic variables relative to baseline. Linear mixed effects models were used to estimate post-initiation trends in absolute units from 2 to 24\u00a0h, accounting for repeated measures within patients and adjusting for age, ventricular assist device status, milrinone exposure, and circulatory physiology. Unsupervised clustering using Ward linkage was performed on percent change features to assess heterogeneity in response. Fifty-nine patients were included in the final analyses. Following sacubitril\/valsartan initiation, heart rate and systolic blood pressure decreased while diastolic and mean arterial pressure increased. Central venous pressure rose over time. Measures of systemic oxygen delivery improved, including pulse oximetry and renal near-infrared spectroscopy (NIRS), with the largest effect observed in renal NIRS. These changes were consistent across models and remained significant after adjustment. Clustering identified two response patterns, reflecting differences in magnitude rather than distinct physiologic phenotypes. Sacubitril\/valsartan initiation in critically ill children is associated with coordinated changes in arterial, venous, and tissue-level physiology consistent with improved systemic oxygen delivery. The response appears continuous, with variability in magnitude across patients rather than discrete phenotypes.<\/jats:p>","DOI":"10.1007\/s00246-026-04470-2","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:02:14Z","timestamp":1790222534000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The hemodynamic effects of sacubitril\/valsartan in the first 24\u00a0h of initiation in pediatric cardiac intensive care unit patients: insights using high-fidelity data"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1050-3416","authenticated-orcid":false,"given":"Adam","family":"Morrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit S.","family":"Loomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Mejia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Szarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krysta","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesam","family":"Sourour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"4470_CR1","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1161\/CIRCULATIONAHA.123.066605","volume":"150","author":"R Shaddy","year":"2024","unstructured":"Shaddy R, Burch M, Kantor PF et al (2024) Sacubitril\/valsartan in pediatric heart failure (PANORAMA-HF): a randomized, multicenter, double-blind trial. Circulation 150:1756\u20131766. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.066605","journal-title":"Circulation"},{"key":"4470_CR2","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1002\/ehf2.15326","volume":"12","author":"R Shaddy","year":"2025","unstructured":"Shaddy R, Gong J, Garito T et al (2025) Association between NT-proBNP changes and clinical outcomes in paediatric patients with heart failure: Insights from PANORAMA-HF and PARADIGM-HF. ESC Heart Fail 12:3042\u20133052. https:\/\/doi.org\/10.1002\/ehf2.15326","journal-title":"ESC Heart Fail"},{"key":"4470_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ahj.2017.07.006","volume":"193","author":"R Shaddy","year":"2017","unstructured":"Shaddy R, Canter C, Halnon N et al (2017) Design for the sacubitril\/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study). Am Heart J 193:23\u201334. https:\/\/doi.org\/10.1016\/j.ahj.2017.07.006","journal-title":"Am Heart J"},{"key":"4470_CR4","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/j.cjca.2013.08.008","volume":"29","author":"PF Kantor","year":"2013","unstructured":"Kantor PF, Lougheed J, Dancea A et al (2013) Presentation, diagnosis, and medical management of heart failure in children: Canadian Cardiovascular Society guidelines. Can J Cardiol 29:1535\u20131552. https:\/\/doi.org\/10.1016\/j.cjca.2013.08.008","journal-title":"Can J Cardiol"},{"key":"4470_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1274990","volume":"10","author":"Y Xu","year":"2023","unstructured":"Xu Y, Zhang M, Chen Y et al (2023) Does sacubitril\/valsartan work in children with heart failure?-a pilot study. Front Cardiovasc Med 10:1274990. https:\/\/doi.org\/10.3389\/fcvm.2023.1274990","journal-title":"Front Cardiovasc Med"},{"key":"4470_CR6","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.healun.2024.01.012","volume":"43","author":"ZE Hale","year":"2024","unstructured":"Hale ZE, Prichett L, Jandu S, Ravekes W (2024) Sacubitril-valsartan vs ACE\/ARB in pediatric heart failure: A retrospective cohort study. J Heart Lung Transpl Off Publ Int Soc Heart Transpl 43:826\u2013831. https:\/\/doi.org\/10.1016\/j.healun.2024.01.012","journal-title":"J Heart Lung Transpl Off Publ Int Soc Heart Transpl"},{"key":"4470_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-025-03938-x","author":"A Konduri","year":"2025","unstructured":"Konduri A, Duimstra A, Lowery R et al (2025) Single-center experience with sacubitril\/valsartan in patients with congenital heart disease. Pediatr Cardiol. https:\/\/doi.org\/10.1007\/s00246-025-03938-x","journal-title":"Pediatr Cardiol"},{"key":"4470_CR8","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s00246-023-03138-5","volume":"45","author":"RS Loomba","year":"2024","unstructured":"Loomba RS, Ikeda N, Dorsey V et al (2024) Acute Effects of Sacubitril\/Valsartan with Initial Initiation in Pediatric Patients in the Cardiac Intensive Care Unit. Pediatr Cardiol 45:1359\u20131363. https:\/\/doi.org\/10.1007\/s00246-023-03138-5","journal-title":"Pediatr Cardiol"},{"key":"4470_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/9781444311822","volume-title":"Congenital diseases of the heart: clinical-physiological considerations","author":"AM Rudolph","year":"2009","unstructured":"Rudolph AM (2009) Congenital diseases of the heart: clinical-physiological considerations, 3rd edn. Wiley-Blackwell, Chichester, UK Hoboken, NJ","edition":"3"},{"key":"4470_CR10","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1007\/s00246-023-03127-8","volume":"44","author":"RS Loomba","year":"2023","unstructured":"Loomba RS (2023) The Oximetric Approach to Clinical Care. Pediatr Cardiol 44:960\u2013961. https:\/\/doi.org\/10.1007\/s00246-023-03127-8","journal-title":"Pediatr Cardiol"},{"key":"4470_CR11","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray JJV, Packer M, Desai AS et al (2014) Angiotensin\u2013Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med 371:993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"4470_CR12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/eurheartj\/eht466","volume":"35","author":"M Volpe","year":"2014","unstructured":"Volpe M, Rubattu S, Burnett J (2014) Natriuretic peptides in cardiovascular diseases: current use and perspectives. Eur Heart J 35:419\u2013425. https:\/\/doi.org\/10.1093\/eurheartj\/eht466","journal-title":"Eur Heart J"},{"key":"4470_CR13","volume-title":"Circulatory physiology: cardiac output and its regulation","author":"AC Guyton","year":"1973","unstructured":"Guyton AC (1973) Circulatory physiology: cardiac output and its regulation, 2. ed. Saunders, Philadelphia","edition":"2. ed"},{"key":"4470_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-016-1438-7","volume":"20","author":"S Magder","year":"2016","unstructured":"Magder S (2016) Volume and its relationship to cardiac output and venous return. Crit Care 20:271. https:\/\/doi.org\/10.1186\/s13054-016-1438-7","journal-title":"Crit Care"},{"key":"4470_CR15","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/pan.14350","volume":"32","author":"RS Loomba","year":"2022","unstructured":"Loomba RS, Flores S (2022) Oximetry titrated care: This is the way. Paediatr Anaesth 32:485. https:\/\/doi.org\/10.1111\/pan.14350","journal-title":"Paediatr Anaesth"},{"key":"4470_CR16","volume-title":"Currency of Care: Oxygen Delivery in the PCICU","author":"R Loomba","year":"2025","unstructured":"Loomba R (2025) Currency of Care: Oxygen Delivery in the PCICU, 1st ed. Arashi Publishing, Chicago, IL","edition":"1st ed"},{"key":"4470_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1177\/0091270009343932","volume":"50","author":"J Gu","year":"2010","unstructured":"Gu J, Noe A, Chandra P et al (2010) Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 50:401\u2013414. https:\/\/doi.org\/10.1177\/0091270009343932","journal-title":"J Clin Pharmacol"},{"key":"4470_CR18","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1016\/j.ddstr.2013.11.002","volume":"9","author":"TH Langenickel","year":"2012","unstructured":"Langenickel TH, Dole WP (2012) Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure. Drug Discov Today Ther Strateg 9:e131\u2013e139. https:\/\/doi.org\/10.1016\/j.ddstr.2013.11.002","journal-title":"Drug Discov Today Ther Strateg"},{"key":"4470_CR19","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1161\/CIRCULATIONAHA.123.066605","volume":"150","author":"R Shaddy","year":"2024","unstructured":"Shaddy R, Burch M, Kantor PF et al (2024) Sacubitril\/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial. Circulation 150:1756\u20131766. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.066605","journal-title":"Circulation"},{"key":"4470_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2024.102926","volume":"50","author":"H Zha","year":"2025","unstructured":"Zha H, Zhai X, Wang L et al (2025) Transforming pediatric heart failure: efficacy of low-dose sacubitril\/valsartan. Curr Probl Cardiol 50:102926. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102926","journal-title":"Curr Probl Cardiol"},{"key":"4470_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/pan.14328","volume":"32","author":"J Karlsson","year":"2022","unstructured":"Karlsson J, L\u00f6nnqvist P-A (2022) Blood pressure and flow in pediatric anesthesia: An educational review. Paediatr Anaesth 32:10\u201316. https:\/\/doi.org\/10.1111\/pan.14328","journal-title":"Paediatr Anaesth"}],"container-title":["Pediatric Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-026-04470-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00246-026-04470-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-026-04470-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:03:12Z","timestamp":1790265792000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00246-026-04470-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":21,"alternative-id":["4470"],"URL":"https:\/\/doi.org\/10.1007\/s00246-026-04470-2","relation":{},"ISSN":["0172-0643","1432-1971"],"issn-type":[{"value":"0172-0643","type":"print"},{"value":"1432-1971","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"8 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Rohit Loomba is an Editorial Board Member with this journal; Associate Editor.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}